Introducing The Spin Cycle—your new monthly source for insights and updates from BioSurfaces! Each month, we’ll rotate in fresh information on advancements like our 100% animal-free Bio-Spun™ Scaffolds, engineered for superior reliability in tissue models. Stay tuned to discover innovative solutions that drive research and in vivo success! https://lnkd.in/eq9y7cNC #TheSpinCycle #BioSpun #3DCellCulture #AnimalFree #CellTherapy #Innovation #Biotech #Research
BioSurfaces, LLC
Nanotechnology Research
Ashland, Massachusetts 1,034 followers
Nanomaterial Solutions
About us
BioSurfaces, based in Ashland, Massachusetts, is a life science company with deep leadership and a diverse team of specialists. The company’s proprietary electrospinning technology known as Bio-Spun™ creates product solutions by engineering biology with synthetic cellular matrices for applications ranging from IVRT and delivery of bio-active therapeutics to medical devices and consumer health products. These materials can be made to form a variety of unusual and difficult-to-manufacture shapes while also demonstrating improved biocompatibility over other textile-based materials. The BioSurfaces manufacturing process also allows the incorporation of drugs or other bioactive agents directly into the nanofibers for localized release. BioSurfaces’ technology is validated by leading organizations in pharmaceuticals, medical devices, life sciences, and consumer products.
- Website
-
https://www.biosurfaces.us/
External link for BioSurfaces, LLC
- Industry
- Nanotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Ashland, Massachusetts
- Type
- Privately Held
- Founded
- 2003
Locations
-
Primary
200 Homer Avenue
Unit 1P
Ashland, Massachusetts 01721, US
Employees at BioSurfaces, LLC
Updates
-
Dr. Jayashree Chakravarty recently presented our innovative Bio-Spun™ Cell Chamber (BSCC) at the IPITA conference, showcasing its unique ability to promote tissue integration, reduce fibrosis, and provide immune protection. This tri-layer electrospun device is optimized for encapsulating human pancreatic islets, aiming to support long-term viability and glucose-responsive insulin secretion without immunosuppression. Explore the full poster on our website to learn more about this promising solution for cell-based therapies in Type 1 Diabetes. https://lnkd.in/ebseQAu6 #BioSpun #CellTherapy #T1D #DiabetesResearch #TissueEngineering #RegenerativeMedicine #IPITA #MedicalInnovation #FibrosisReduction
-
Excited to announce Dr. Jayashree Chakravarty will present our innovative Bio-Spun™ Cell Chamber at #iPITA2024 in Boston! Her poster shows promising data on this device’s potential to support Type 1 diabetes treatment by promoting tissue integration and minimizing immune response. Check it out next week, or find it on our site soon! https://lnkd.in/eDbJiS7Q #Biotech #DiabetesResearch #NextGenTech #Innovation
-
John Arderne (1307–1392), an English surgeon and one of the pioneers of surgery, is known for developing treatments for various conditions, including "Fistula in Ano," a painful abnormal passage between the rectum and the skin around the anus. His surgical techniques and the use of anesthetics, such as opium and hemlock, were groundbreaking for his time. Today, innovations like the Bio-Spun™ Fistula Plug continue the tradition of advanced treatments for such conditions, offering modern, biocompatible solutions. Click below to learn more about the Bio-Spun™ Fistula Plug. https://lnkd.in/dfdneW3V #MedicalInnovation #SurgicalPioneer #FistulaTreatment #BioSpunTechnology #ModernMedicine (Picture below of medical equipment that was used during Arderne's time)
-
Discover how a Quality Management System (QMS) ensures consistent, reliable products in the manufacturing world. Learn how companies like BioSurfaces streamline their processes using electronic QMS platforms like Greenlight Guru to meet stringent standards and maintain quality. Read the full blog to explore the benefits and implementation strategies! https://lnkd.in/edy2m-3F #QualityManagement #QMS #Manufacturing #MedicalDevices #ProductReliability
-
BioSurfaces’ In Vitro Research Tools (IVRT) platform is currently in the early stage of the product adoption curve, targeting innovators and early adopters in bioengineering and research. Our Bio-Spun™ scaffold is the first scaffold proven in vivo (pre-clinical) to demonstrate material capability for cell integration, it offers groundbreaking potential for research. By engaging with early users, BioSurfaces is refining its tools and gathering valuable feedback to ensure future success. The goal is to continue pushing the platform forward and, over time, expand to broader market adoption, eventually establishing it as the industry standard for in vitro research. For more information on our IVRT platform go check out the posters we have presented at conferences using the link below. https://lnkd.in/e8uWx5nA #InnovativeResearch #InVitroSuccess #BroaderAdoption #IndustryStandard #CellIntegration
-
Building a business is like building with Legos—each piece adds to the vision, with plenty of changes and adjustments along the way. We're excited to keep assembling our Bio-Spun™ IVRT product line and look forward to sharing more as it evolves. Go check out what's new at BioSurfaces in the latest blog! https://lnkd.in/efHvVnss #BioTech #ProductDevelopment #BioSpun #IVRT #BuildingTheFuture
-
The prevalence of inflammatory bowel disease (IBD) in 2023 is estimated to be 825 per 100,000 people, with 410 per 100,000 for Crohn's disease and 414 per 100,000 for ulcerative colitis. We are hopeful that, with early-stage preclinical success, the Bio-Spun™ Fistula Plug will one day be able to help thousands of individuals affected by these diseases. For more information check out our website. If you have any questions please feel free to reach out to us! https://lnkd.in/dfdneW3V #IBDAwareness #CrohnsAndColitis #ChronicIllness #MedicalInnovation #FistulaTreatment
-
We are thrilled to present our groundbreaking work on the Bio-Spun™ Cell Chamber (BSCC) at the IPITA Summit! This innovative electrospun composite cell chamber is designed to promote tissue integration, minimize fibrosis, and provide immunoprotection—addressing critical challenges in islet cell transplantation for Type 1 Diabetes (T1D) patients. In early studies, the BSCC showed sustained biotherapeutic release for over 14 months without the need for immunosuppression or fibrosis! We are now optimizing this technology for human pancreatic islet cells to further advance β-cell replacement therapy. Stay tuned for updates as we continue testing this device in vivo. Success in our animal models could revolutionize T1D treatment! 📍Location: Boston, MA [IPITA Summit] 📅 Date: October 28-29, 2024 #T1DResearch #Bioengineering #DiabetesCare #IsletCellTransplantation #BSCC #InnovativeHealthcare #BiomedicalEngineering Funded by SBIR Phase I grant from NIDDK (Grant #R43DK137616). Special thanks to NIDDK-funded Integrated Islet Distribution Program at City of Hope.
-
Heart failure affects over 6.8 million Americans, with 960,000 new cases diagnosed annually. Of these, 50,000 to 100,000 patients are in late-stage heart failure, with only 8% surviving two years without a heart transplant or assist device. While heart support devices are advancing, the vascular grafts connecting them haven't seen significant improvement in 70 years. Our NuSpun™ Vascular Graft is designed to enhance these connections, aiming to reduce complications and shift assist devices from "bridge to transplant" to "destination therapy." Check out our NuSpun™ Vascular Graft along with our other devices using the link below. https://lnkd.in/dfdneW3V #HeartFailure #MedicalInnovation #NuSpunGraft #DestinationTherapy